Jamieson is pleased to announce it has advised the management team of Atmas Health on the management incentive plan in connection with the divestiture of Baxter International’s (NYSE:BAX) Vantive (formerly Vantive Kidney Care) segment to Carlyle. Atmas Health is a healthcare investment platform formed by Carlyle in 2022.
Vantive is a vital organ therapy company on a mission to extend lives and expand possibilities for patients and care teams everywhere. Vantive delivers innovative products, digitally-enhanced solutions and advanced services to support dialysis at home and in the clinic, as well as critical care therapy to support the kidney and other vital organs in an intensive care unit (ICU) setting.
Michael Sirkin, Mark Wasserberger, and Evan Alper advised the management team on the transaction.
